Alterations in the Ca toolkit in oesophageal adenocarcinoma.

AIM

To investigate alterations in transcription of genes, encoding Ca toolkit proteins, in oesophageal adenocarcinoma (OAC) and to assess associations between gene expression, tumor grade, nodal-metastatic stage, and patient survival.

METHODS

The expression of 275 transcripts, encoding components of the Ca toolkit, was analyzed in two OAC datasets: the Cancer Genome Atlas [via the University of Alabama Cancer (UALCAN) portal] and the oesophageal-cancer, clinical, and molecular stratification [Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS)] dataset. Effects of differential expression of these genes on patient survival were determined using Kaplan-Meier log-rank tests. OAC grade- and metastatic-stage status was investigated for a subset of genes. Adjustment for the multiplicity of testing was made throughout.

RESULTS

Of the 275 Ca-toolkit genes analyzed, 75 displayed consistent changes in expression between OAC and normal tissue in both datasets. The channel-encoding genes, -methyl--aspartate receptor 2D (), transient receptor potential (TRP) ion channel classical or canonical 4 (), and TRP ion channel melastatin 2 () demonstrated the greatest increase in expression in OAC in both datasets. Nine genes were consistently upregulated in both datasets and were also associated with improved survival outcomes. The 6 top-ranking genes for the weighted significance of altered expression and survival outcomes were selected for further analysis: voltage-gated Ca channel subunit α 1D (), voltage-gated Ca channel auxiliary subunit α2 δ4 (), junctophilin 1 (), acid-sensing ion channel 4 (), , and secretory pathway Ca ATPase 2 (). , , and were also upregulated in advanced OAC tumor grades and nodal-metastatic stages in both datasets.

CONCLUSIONS

This study has unveiled alterations of the Ca toolkit in OAC, compared to normal tissue. Such Ca signalling findings are consistent with those from studies on other cancers. Genes that were consistently upregulated in both datasets might represent useful markers for patient diagnosis. Genes that were consistently upregulated, and which were associated with improved survival, might be useful markers for patient outcome. These survival-associated genes may also represent targets for the development of novel chemotherapeutic agents.